Publications from the Christchurch Stem Cell Transplant Programme
- Beard M.E.J. Bone Marrow Transplantation: Technique and Current Indications. NZ Med.J. 91: 99-103; 1980.
- Darlow B.A., Abbott G.D., Beard M.E.J., Fox H.W.J. & Hamer J.W. Bone Marrow Transplantation for severe aplastic anaemia. NZ Med.J. 91: 86-89; 1980.
- Stewart R.J., Duley J.A., Aallardyce R.A., Beard M.E.J. & Fitzgerald P.H. The wound fibroblast and macrophage II. Their origin studied in a human after bone marrow transplantation. Br.J.Surg. 68: 129-131; 1981.
- Beard M.E.J., Heaton D.C., Hamer J.W., Watson J., Abbott G.D., Bremner J., & Snape L. Right atrial catheters for long-term venous access. NZ Med.J. 93: 41-43; 1981.
- Beard M.E.J., Heaton D.C., Hamer J.W., Watson J., Fox H.W.J., Crosier P.S. & Abbott G.D. Bone marrow transplantation for acute leukaemia and severe marrow aplasia: An analysis of five patients. NZ Med.J. 94: 249-252; 1981.
- Hollings PE, Fitzgerald PH, Heaton DC & Beard ME. Host origin of in-vitro bone marrow fibroblasts after marrow transplantation in man. International Journal of Cell Cloning 1984; 2: 348-355.
- Heslop HE, Heaton DC, Hart DNJ, Allen JR, Abbott GD & Beard ME. Allogeneic bone marrow transplantation at Christchurch 1979-1985. New Zealand Medical Journal 1986; 99: 318-321.
- Beard ME. Bone marrow transplantation (review). New Zealand Medical Journal 1987; 100: 486-488.
- Jeffrey GM, Beard ME, Ikram RB, Chua J, Allen JR, Heaton DC, Hart DNJ & Schousboe MI. Intranasal amphotericin B reduces the frequency of invasive aspergillosis in neutropenic patients. Am J Medicine 1991; 90: 685-692.
- Baker BW, Wilson CL, Davis AL, Spearing RL, Hart DNJ, Heaton DC & Beard ME. Busulphan/cyclophosphamide conditioning for bone marrow transplantation may lead to failure of hair regrowth. Bone marrow transplantation 1991; 7: 43-47
- Beard ME, Inder AB, Allen JR, Hart DNJ, Heaton DC & Spearing RL. The costs and benefits of bone marrow transplantation. New Zealand Medical Journal 1991; 104: 303-305.
- Baker BW, Smith MP, Abbott GD, Beard ME, Spearing RL & Heaton DC. Aplastic anaemia in Christchurch Hospital 1979-89. New Zealand Medical Journal 1991; 104: 468-470.
- New Zealand Bone Marrow Transplantation Study Group. Bone marrow transplantation in New Zealand. Bone Marrow Transplantation 1994; 13: 733-736.
- Hill GR, Hart DNJ, Moore AF & Morris CM. Donor leucocyte infusions in the treatment of chronic myeloid leukaemia in relapse post bone marrow transplantation. Pathology 1996; 28: 51-53.
- Hill GR, Inder A, Patton WN & Hart DNJ. High dose therapy and autologous bone marrow versus blood cell rescue. New Zealand Med J 1996; 109: 445-448.
- Snowden JA, Patton WN, O’Donnell JL, Hannah EE & Hart DNJ. Prolonged remission of longstanding systemic lupus erythematosis after autologous bone marrow transplant for non-Hodgkins lymphoma. Bone Marrow Transplantation 1997; 19: 1247-1250.
- Manley R, Fearnley D, Patton WN, Newhook C, Spearing RL & Hart DNJ. Syngeneic peripheral blood stem cell transplantation for severe aplastic anaemia. Bone Marrow Transplantation 1997; 20: 1009-1010.
- Snowden JA & Heaton DC. Development of psoriasis after syngeneic bone marrow transplants from psoriatic donor: further evidence of adoptive autoimmunity. Br J Dermatology 1997; 137: 130-132.
- Withington S, Chambers ST, Beard ME, Inder A, Allen JR, Ikram RB, Schousboe MI, Heaton DC, Spearing RL & Hart DNJ. Invasive aspergillosis in severely neutropenic patients over 18 years: Impact of intranasal amphotericin B and HEPA filtration. Journal of Hospital Infection 1998; 38: 11-18.
- Fearnley DB, Whyte LF, Carnoutsos SA, Cook AH & Hart DNJ. Monitoring human blood dendritic cell numbers in normal individuals and in stem cell transplantation. Blood 1999; 93: 1-10.
- McLean FR, Hanley JP, Patton WN, Hart DNJ, Langley S, Bayston K & Jeffery GM. Successful high dose therapy for relapsed mediastinal large B cell lymphoma following surgical repair of anterior chest wall defect. Clin lab Haematol 2000;22:1-3
- Snowdon JA, Hill GR, Hunt P, Carnoutsos S, Spearing RL, Espiner E & Hart DNJ. Assessment of cardiotoxicity during haematopoietic stem cell transplantation with plasma brain natriuretic peptide. Bone Marrow Transplantation 2000;26:309-313.
- Stevens JM, Patton WN, Heaton DC, Spearing RL, Shaw G, Bowie D, Smyth D & Comenzo R. Autologous PBSCT in patients with cardiac amyloidosis. Bone Marrow transplantation 2000;26:588-589.
- Hock BD, Haring LF, Ebbett AM, Patton WN & McKenzie JL. Differential effects of G-CSF mobilisation on dendritic cell subsets in normal allogeneic donors and patients undergoing autologous transplantation. Bone Marrow Transplantation 2002; 30: 733-740.
- Chee L, Spearing RL, Morris C, McDonald M, Hanrahan V, Ebbett A, Scott R, Florkowski C, Walmsley T & Patton WN. Acquired myeloma-associated Type III hyperlipidaemia treated by nonmyeloablative HLA-identical sibling allogeneic stem cell transplant using a donor with essential thrombocythaemia (ET): Evidence of engraftment without manifestation of ET in recipient. Bone Marrow Transplantation 2005; 35: 1213-1214.
- Sullivan M, Browett P & Patton N. Private umbilical cord blood banking: a biological insurance of dubious future benefit! New Zealand Med J, 2005;117:no 1208. http://www.nzma.org.nz/journal/118-1208/1260/ © NZMA.
- Blacklock H, Teague L, Patton N & Browett P. Volunteer cord blood banking and transplantation. New Zealand Med J, 2005;117:no 1208. URL:http://www.nzma.org.nz/journal/117-1208/1255/ © NZMA
- Chambers ST, Sanders J, Patton WN, et al. Reduction of exit-site infections of tunnelled intravascular catheters among neutropenic patients by sustained-release chlorhexidine dressings: results from a prospective randomized controlled trial. J Hosp Infect 2005;61(1):53-61.
- Nieto Y, Patton WN, Hawkins T, Spearing RL, Bearman SI, Rabinovitch R, Zeng C, Baron A & McSweeney PA. Tacrolimus and mycophenolate mofetil after non-myeloablative matched sibling donor allogeneic stem-cell transplants conditioned with fludarabine and low-dose total body irradiation. Biol Blood Marrow Transplant 2006 12:217-225.
- S Feyler, HM Prince, R Pearce, K Towlson, I Nivison-Smith, S Schey, J Gibson, N Patton, K Bradstock, DI Marks and G Cook, on behalf of the BSBMT & ABMTRR. The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. Bone Marrow Transplantation (2007) 40, 443–450
- Sanders, J., Pithie, A., Ganly, P., Surgenor, L., Wilson, R., Merriman, E., Loudon, G., Judkins, R. and Chambers, S. A prospective double blind randomised trial comparing intraluminal ethanol with heparinised saline for the prevention of catheter-associated blood stream infection in immunosuppressed haematology patients. Journal of Antimicrobial Chemotherapy (2008) prepublished on line, July 11 2008.
- Marr H., McDonald E-J., Merriman E., Smith M., Mangos H., Stoddart C., Ganly P. Successful treatment of transplant associated microangiopathy with rituximab. New Zealand Medical Journal 2009; 122, No:1292, 72-74
- Hernandez E., Ganly P., Charu V., DiBeneditto J., Tomita D., Lillie T., Taylor K. Randomised, Double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anaemia. Current Medical Research and Opinion 2009; 25, No:9, 2109-2120
- Nivison-Smith, I., et al. (2011). "Allogeneic hematopoietic cell transplant for multiple myeloma using reduced intensity conditioning therapy, 1998-2006: factors associated with improved survival outcome." Leuk Lymphoma 52(9): 1727-1735.
- Trengrove, A. M., J. E. Schouten, et al. (2012). "Comparing Pegylated and Conventional G-CSF in the Mobilisation of PBSC in Patients with Myeloma." Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation 18(2): S384-S385.
- Fernyhough, L. J., V. A. Buchan, et al. (2013). "Relative recovery of haematopoietic stem cell products after cryogenic storage of up to 19 years." Bone Marrow Transplant 48(1): 32-35.
- Fernyhough, L. J., B. D. Hock, et al. (2013). "Survival of myeloma patients following the introduction of thalidomide as a second-line therapy: a retrospective study at a single New Zealand centre." Intern Med J 43(2): 130-137.
- Ganly, P., et al. (2014). "Outcomes of allogeneic haematopoietic stem cell transplants at a small New Zealand centre - does size matter?" ntern Med J 44(7): 683-689.
- Butler, A. and A. Thurston (2015). "CMV and EBV Reactivation after Allogeneic Transplantation." Biology of Blood and Marrow Transplant 21(2): S244.
- Patton, W. N., et al. (2016). "Graft Transit Time has no Effect on Outcome in Unrelated Donor Myeloablative Haematopoietic Cell Transplants (HCT) Performed in Australia and New Zealand: An Australasian Bone Marrow Transplant Recipient Registry (ABMTRR) Study." Biology of Blood and Marrow Transplant 22(3): S345-S346.
|
Updated to include recent publications.
|
Meghan Heaphy
|